Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Update

22 Nov 2023 07:00

RNS Number : 2049U
Plant Health Care PLC
22 November 2023
 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

Trading update

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is announcing an update on trading and the outlook for the full year to 31 December 2023 ("FY23").

 

Highlights

 

· Market conditions in the wider agriculture market have diminished over the course of the year, particularly in the recent months;

· Due to these challenging market conditions, particularly in the key USA end market, the Company now anticipates revenue in FY2023 to be in line with or show modest growth over the year ended 31 December 2022 ("FY22"); 

· The Company continues to make significant progress in obtaining new product registrations and widening geographic distribution, positioning the Company well for growth in 2024 and beyond;

· Trading in Brazil, Mexico and Europe broadly in line with market expectations.

 

As highlighted at the time of the Company's interim results in September 2023, market conditions for traditional agriculture input businesses were extremely challenging in the first half of the year, and the environment has continued to deteriorate over recent months. This has been particularly evident in the US; however, global markets, including Brazil, Europe and some Asian markets, have also been subdued, leading a number of companies across the sector to revise guidance on current year performance.

 

Pleasingly, Plant Health Care's trading in Brazil, Mexico and Europe has been broadly in line with market expectations in the second half of the year, in spite of these challenging market conditions. However, sales orders in the US have not materialised as originally anticipated as the Company's distribution partners in the region have gone through a significant inventory correction. This has, in large part, been driven by volatility in demand and price following the global COVID-19 pandemic, as well as the effects of an increasing interest rate environment and change in growers purchasing habits. Distributors are shifting demand from Q4 FY23 into H1 FY24 and are planning to manage lower levels of inventory for FY24. While inventories of the Company's products with distributors are not high, it is not immune to this structural change. In addition, regulatory delays in India and a number of other countries have resulted in delays to some product launches; whilst this is expected to have a limited impact on the Company in FY23, this is likely to affect performance more materially in FY24.

 

Accordingly, the Board now anticipates revenue for FY23 to show flat to modest growth over FY22, with the final result dependent on the timing of expected orders. Revenue in FY24 is now anticipated to be approximately 28% lower than market expectations of $23m, due to lower levels of inventory being maintained by the Company's distributors and regulatory delays in some territories. The Board intends to review operating expenses accordingly.

 

Against this backdrop, the pace of new product registrations and the widening of distribution partnerships into new geographies continues. Sales of Harpin£ are increasing in all of the Company's core markets, excluding the US market. Critically, the first products from the new PREtec platform are being well received in the market, with successful product launches across three continents. Although there are some delays to product launches, the growth trajectory is clear for the medium term. After more than 10 years and an investment in excess of $30m, PREtec product adoption is poised for a significant step up from distributors and end customers. Accordingly, the Board is confident that order intake will increase once our customers have corrected their inventory levels.

 

Jeff Tweedy, Chief Executive Officer, commented:

 

"Sales of Plant Health Care products experienced significant growth in all regions with the exception of the US market. Deteriorating market conditions driven by distributor destocking of channel inventories impacted PHC sales in the US. Registration delays have impacted our 2024 outlook; however, we remain positive on the revenue growth opportunities for our technology. PHC now markets PREtec on three continents and we anticipate the launch of Teikko in Brazil during the 2024/2025 growing season."

 

For further information, please contact:

 

Plant Health Care plc

Tel: +1 919 926 1600

Jeff Tweedy, CEO

 

Cavendish Capital Markets Limited - Nomad & Broker

Tel: +44 (0) 131 220 9771

Neil McDonald / Peter Lynch

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes, and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAORROSUAUUA
Date   Source Headline
12th Nov 20193:56 pmRNSHolding(s) in Company
6th Nov 201912:57 pmRNSInvestment in Company by Ospraie Ag Science LLC
30th Oct 20197:00 amRNSAppointment of new Board Directors
3rd Oct 20192:50 pmRNSDirector/PDMR Shareholding
30th Sep 20197:00 amRNSInterim Report ended 30 June 2019
9th Sep 20197:00 amRNSPilot production of PREtec peptides
19th Aug 20197:00 amRNSBlock listing Interim Review
15th Aug 20197:00 amRNSProgress with PREtec field trials in Brazil
5th Aug 20195:18 pmRNSHolding(s) in Company
25th Jun 20197:00 amRNSNew Distribution Agreement with Wilbur-Ellis
12th Jun 201911:05 amRNSResult of AGM
30th Apr 20194:19 pmRNSAnnual Report & Accounts and AGM Notice Published
10th Apr 20197:00 amRNSResults for the year ended 31 December 2018
27th Mar 20193:41 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSNew Technology Update
19th Feb 20197:00 amRNSBlock listing Interim Review
29th Jan 20197:00 amRNSTrading Statement
24th Jan 20195:58 pmRNSHolding(s) in Company
21st Dec 20187:00 amRNSTrading Statement
28th Nov 20187:00 amRNSNew Technology Update
21st Nov 20187:00 amRNSPlant Health Care ProAct® Wins Top Industry Award
19th Nov 20187:00 amRNSPlant Health Care to present at Mello London
14th Nov 20187:00 amRNSPositive Developments with Harpin
8th Nov 20187:00 amRNSChange of Adviser
5th Nov 20187:00 amRNSHolding(s) in Company
18th Sep 20187:00 amRNSInterim Report ended 30 June 2018
12th Sep 20187:00 amRNSUS Announces Harpin aß Product Launch in Corn
20th Aug 20187:00 amRNSBlock listing Interim Review
30th Jul 20187:00 amRNSUpdate on sugarcane in Brazil
16th Jul 20187:00 amRNSTrading Statement
6th Jun 20182:39 pmRNSHolding(s) in Company
6th Jun 201811:14 amRNSResult of AGM
30th May 20187:00 amRNSGrant of Options
4th May 20185:59 pmRNSHolding(s) in Company
30th Apr 20183:11 pmRNSPublication of Annual Report and Notice of AGM
10th Apr 20187:00 amRNSResults for the year ended 31 December 2017
8th Mar 20187:00 amRNSBlock listing Interim Review
7th Mar 20183:07 pmRNSHolding(s) in Company
7th Mar 20183:06 pmRNSHolding(s) in Company
7th Mar 20183:02 pmRNSHolding(s) in Company
2nd Mar 20185:48 pmRNSHolding(s) in Company
27th Feb 20184:12 pmRNSResult of Placing and Subscription
27th Feb 20187:00 amRNSProposed Placing and Subscription
24th Jan 20187:00 amRNSTrading Statement
12th Dec 20177:00 amRNSNew Technology Update
8th Dec 20174:35 pmRNSPrice Monitoring Extension
6th Dec 20174:40 pmRNSSecond Price Monitoring Extn
6th Dec 20174:35 pmRNSPrice Monitoring Extension
18th Sep 20177:00 amRNSHalf-year Report
21st Aug 20177:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.